Search
Acadesine
go.drugbank.com/drugs/DB04944InvestigationalAcadesine (AICA-riboside) is a purine nucleoside analog with anti-ischemic properties that is currently being studied (Phase 3) for the prevention of adverse cardiovascular outcomes in patients undergoing … It is being developed jointly by PeriCor and Schering-Plough. Acadesine has been granted Orphan Drug Designation for B-CLL in the EU.
Dilmapimod
go.drugbank.com/drugs/DB12140InvestigationalDilmapimod (SB-681323) is a p38 MAP-kinase inhibitor that has potential uses in inflammatory conditions such as RA (Rheumatoid Arthritis).
Cinolazepam
go.drugbank.com/drugs/DB01594InvestigationalCinolazepam is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant activity. It is not approved in Canada or America.
XL019
go.drugbank.com/drugs/DB05243InvestigationalXL019 is a selective inhibitor of the cytoplasmic tyrosine kinase JAK2. An IND for XL019 was filed by Exelixis in May 2007.
Telapristone acetate
go.drugbank.com/drugs/DB05253InvestigationalTelapristone acetate, an orally-available, selective progesterone receptor modulator, is in development to alleviate symptoms associated with both uterine fibroids and endometriosis.
Branaplam
go.drugbank.com/drugs/DB14918InvestigationalBranaplam is under investigation in clinical trial NCT02268552 (An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA)).
TG-1042
go.drugbank.com/drugs/DB18435InvestigationalTG-1042 (formerly known as ASN-002) is a recombinant adenovirus carrying the cDNA coding sequence for the human interferon gamma gene.
Synonyms: Ad-IFNγTPX-4589
go.drugbank.com/drugs/DB18604InvestigationalTPX-4589 is an antibody-drug conjugate composed of a humanized monoclonal antibody targeting CLDN18.2 and linker-payload MC-VC-PAB-MMAE.
Synonyms: Antibody drug conjugate composed of a humanized monoclonal antibody targeting CLDN18.2 and linker-payload MC-VC-PAB-MMAEEftilagimod alfa
go.drugbank.com/drugs/DB16150InvestigationalEftilagimod alfa is under investigation in clinical trial NCT02614833 (IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma).
Categories: Antigens, Differentiation, T-Lymphocyte, Costimulatory and Inhibitory T-Cell ReceptorsARX517
go.drugbank.com/drugs/DB23076InvestigationalARX517 is under investigation in clinical trial NCT04662580 (ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer).